Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Catalyst Biosciences logo — company profile

Catalyst Biosciences

Founded 1997 United States South San Francisco, United States 12 employees Post Ipo Equity Total: $301.31M Biopharma, Biotechnology +2

General Information

Company Name Catalyst Biosciences
Founded Year 1997
Location United States South San Francisco, United States +1
Founders / Decision Makers
Team member
Employees 12
Industries Biopharma, Biotechnology, Life Sciences +1
Funding Stage Post Ipo Equity
Social

Get notified when Catalyst Biosciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Catalyst Biosciences

Catalyst Biosciences is an innovative biopharmaceutical company founded in 1997, focused on rare disorders of the complement and coagulation systems within the Health Care industry. Their protease engineering platform has yielded significant results, leading to the development of several promising programs. These programs include two late-stage clinical programs in hemophilia, a research program on engineering of subcutaneous (SQ) complement inhibitors, a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a preclinical development program with Biogen for dry age-related macular degeneration (AMD). What makes Catalyst Biosciences stand out is the improved functionality and potency of their products. This enables SQ administration of recombinant coagulation factors and complement inhibitors, low-dose, high activity gene therapy constructs, and less frequently dosed intravitreal therapeutics. The company recently secured a noteworthy $50.00M Post-IPO Equity investment on 27 January 2021, indicating strong investor confidence in their endeavors. With their headquarters in the United States, Catalyst Biosciences continues to make significant strides in addressing unmet medical needs in the field of rare disorders.

Taxonomy: biopharmaceutical, rare disorders, complement system, coagulation system, protease engineering, clinical development, hemophilia, gene therapy, Factor IX, macular degeneration, recombinant coagulation factors, complement inhibitors, intravitreal therapeutics

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 27 Jan 2021
Post-IPO Debt •••••• - 11 Jun 2015
Post-IPO Equity •••••• - 03 Feb 2015
Post-IPO Equity •••••• - 22 Apr 2014
Post-IPO Equity •••••• - 20 Aug 2013

View All 14 Funding Rounds

Catalyst Biosciences Alternatives & Competitors

Catalyst Biosciences vs
Complement Therapeutics
Complement Therapeutics Germany

Developing the next generation of complement medicines

Series A
36 employees
Biotechnology
Catalyst Biosciences vs
Kanaph Therapeutics
Kanaph Therapeutics Korea South

We are the leader of next generation immuno-oncology and autoimmune diseases.

Series B
16 employees
Biotechnology, Pharmaceutical
Catalyst Biosciences vs
Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd. Canada

Pioneering novel therapies through advanced epigenetic research to fight autoimmune diseases and can...

Unknown
11 employees
Biotechnology, Health Care

FAQ About Catalyst Biosciences

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineer...
Catalyst Biosciences was founded in 1997.
Catalyst Biosciences is headquartered in South San Francisco, United States.
Catalyst Biosciences operates in the following industries: Biopharma, Biotechnology, Life Sciences, Pharmaceutical.
Catalyst Biosciences has approximately 12 employees.
Catalyst Biosciences has completed 14 funding rounds, raising a total of $301.31M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Catalyst Biosciences include Complement Therapeutics, Kanaph Therapeutics, Zenith Epigenetics Ltd., Montis Biosciences, AskBio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Catalyst Biosciences and Complement Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Catalyst Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes